PackGene Biotech, APAC
PackGene Biotech (派真生物) is a China-based gene therapy CRO/CDMO providing AAV, lentivirus, plasmid, and mRNA/LNP services from research to GMP grade, operating dual cGMP facilities in Guangzhou and Houston for biotech and pharma clients globally.
- Company typePrivate
- Founded2014
- HeadquartersGuangzhou (广州), China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PackGene Biotech, APAC does
PackGene Biotech (派真生物) is a China-headquartered gene therapy contract research, development, and manufacturing organization (CRO/CDMO) founded in 2014 by Dr. Li Huapeng (李华鹏) in Guangzhou. The company provides integrated services spanning research-grade to GMP-grade recombinant AAV viral vector packaging, lentivirus packaging, plasmid DNA production, and mRNA/LNP synthesis, with dual cGMP manufacturing facilities in Guangzhou (~13,000 sqm) and Houston, USA (~3,200 sqm). Its core technology rests on three proprietary platforms — π-Alpha 293 AAV high-yield production (5-20x yield improvement), π-Omega plasmid DNA high-yield (2-8x improvement), and π-Icosa AAV serotype screening — supplemented by patented assets including the AAV.eM muscle-targeting capsid, Cre/LoxP minicircle impurity-reduction system, and the PCS3.0 high-yield cell line.
The company operates a hybrid go-to-market model combining direct enterprise field sales for GMP/CDMO contracts (targeting gene therapy biotech and pharma companies) with a self-serve online ordering portal (order.packgene.com) for research-grade products serving academic and industrial research labs. Revenue is generated through project-based CRO contracts (research-grade AAV, lentivirus, mRNA, plasmid preparation priced from 600 CNY for ready-made AAV to 78,800 CNY for large custom batches), GMP/CDMO program fees, and ancillary products such as the ACCUBOX mycoplasma detection kit and host cell DNA residual detection kits. PackGene has delivered 50,000+ AAV projects, supported 25+ IND approvals (FDA and NMPA) with zero supplementary reviews, and served 2,000+ customers across 30+ countries.
The customer base spans Chinese and international gene therapy developers, with marquee enterprise clients such as Biogen and Decibel Therapeutics alongside a long tail of Chinese biotech startups (SineuGene, Lingyi Bio, Genevector, Xingmou Bio, NeuExcell, HuiDa Gene, Ruifeng Bio, Jianda Jiuzhou) progressing AAV-based therapies for ALS, Gaucher disease, ophthalmologic conditions, and other rare diseases through IND and IIT stages. The company has completed 7 funding rounds, with the most recent disclosed being a 100M+ CNY C+ round led by SDIC Capital (国投招商) in December 2023, and holds 80+ filed patents with 50+ granted. ISO 9001/27001/14001/45001 certifications, an MCB DMF filed with FDA, and active conference participation (ASGCT, BIOCHINA, HRSC) round out the operational profile.
PackGene Biotech, APAC firmographics
Firmographics- Name
- PackGene Biotech, APAC
- Legal name
- PackGene Biotech Inc.
- Website
- https://packgene.cn
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PackGene Biotech (派真生物) is a China-based gene therapy CRO/CDMO providing AAV, lentivirus, plasmid, and mRNA/LNP services from research to GMP grade, operating dual cGMP facilities in Guangzhou and Houston for biotech and pharma clients globally.
- Ownership category
- akta.pro rank
PackGene Biotech, APAC industry classification
Industry- Product category
- Gene Therapy CDMO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), Cell Therapy CDMO (HLAGABAD)
Keywords
Where PackGene Biotech, APAC is headquartered
LocationHeadquarters
- HQ city
- Guangzhou (广州)
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
PackGene Biotech, APAC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- AAV Viral Vector CRO Services: Research-grade and NHP-grade AAV packaging services for academic and biotech clients. Services include gene-to-AAV one-stop service, AAV serotype screening, AAV library services, and AAV ready-made (现货) products. Priced per project with quantities ranging from research to NHP-grade.
- AAV GMP/CDMO Manufacturing Services: GMP-grade AAV production from plasmid development through fill-finish. Covers process development, cell banking, upstream/downstream工艺优化, analytical method development, quality release testing, and regulatory filing support. Supports IIT, IND, and commercial BLA stages. China and US cGMP facilities with 10L to 2000L scale.
- mRNA and LNP Services: Custom mRNA synthesis and mRNA-LNP formulation services from research to GMP grade. Includes off-the-shelf mRNA products. Covers design, production, and quality testing across drug and vaccine development stages.
- Lentivirus Packaging Services: Research-grade and animal-grade lentivirus packaging services with delivery in 10-12 working days. qPCR-based titer quantification, full-service safety and shipping support.
- Plasmid DNA Production: Research-grade and preclinical-grade plasmid DNA production. High-purity plasmids for AAV and mRNA production.
- Detection Kits and Reagent Products: ACCUBOX mycoplasma detection kit, host cell DNA residual detection kits (E.coli, HEK293), and other assay reagent kits sold as products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | AAV Packaging (Research Grade): 6-8折 discount range; AAV Packaging (HT Grade): 7.8折; AAV Packaging (NHP Grade): 9折 (for 5E13GC-1E15GC); AAV Packaging Three-guarantee-one: 8折; AAV Ready-made: 8折 discount. |
| Unit Pricing | Pay-as-you-go | AAV Custom Packaging: tiers from 1E+12GC to 1E+14GC, priced 5,980–78,800 CNY per order; AAV Ready-made: 600 CNY (1E+11GC) to 11,200 CNY (1E+13GC); mRNA Custom: 5,000 CNY (50μg) to 65,000 CNY (10mg); mRNA-LNP Custom: 8,980 CNY (100μg) to 82,000 CNY (10mg); Lentivirus Package: starting 1,980 CNY (cell-grade 1E+8TU, within 3k TU). |
| Unit Pricing | Pay-as-you-go | Q4 2025 Double-11 (Nov 11) promotion: AAV packaging 6折起 (regular serotypes, research-grade); AAV three-guarantee-one 7折起 (includes gene synthesis + vector construction + plasmid prep + packaging + titer testing + control virus); Lentivirus 7折 (cell-grade: 5E8TU-1E9TU, animal-grade: 2E8TU-1E9TU); mRNA custom 6折起, ready-made from 400 CNY. |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
PackGene Biotech, APAC product offering
Product offeringCore offering
PackGene Biotech is a one-stop CRO and CDMO platform for gene therapy vectors, providing recombinant AAV, lentivirus, mRNA/LNP, and plasmid DNA services from research-grade through GMP-grade production. Its offering spans vector design, process development, GMP manufacturing (10L-2000L scale), analytical testing (110+ methods), and regulatory CMC support covering IIT, IND, and BLA stages for global gene therapy developers and academic researchers.
Product overview
PackGene Biotech is a one-stop AAV CRO & CDMO platform offering integrated gene therapy vector development and manufacturing services. The portfolio includes three proprietary technology platforms (π-Alpha™ 293 AAV High-Yield Platform, π-Omega™ Plasmid DNA High-Yield Platform, and π-Icosa™ AAV Serotype Screening Platform) supporting a full range of services from research-grade to GMP-grade AAV, lentivirus, and mRNA/LNP production. Downstream offerings span vector design tools (piVector online platform), AAV serotype screening and library services, off-the-shelf AAV products, plasmid preparation, and detection reagent kits. The company operates dual cGMP bases in Guangzhou (13,000 m²) and Houston (3,200 m²) with 6 GMP AAV production lines (10L–2000L scale) and 2 GMP plasmid lines (5L–200L scale), supporting global IND/BLA filings.
Differentiator
Problem solved
Functional benefit
Products and services
- π-Alpha™ 293 AAV High-Yield Production Platform Proprietary high-yield AAV manufacturing platform providing CRO and CDMO clients with 5-20x increases in AAV vector yield and 10x titer improvements through QbD-guided upstream and downstream process optimization, supporting research-grade through GMP-grade production. The platform is positioned as a core enabling technology for PackGene's AAV services and is available as part of integrated AAV manufacturing engagements.
- π-Omega™ Plasmid DNA High-Yield Platform Plasmid DNA production platform supplying high-purity research-grade and preclinical-grade plasmids for AAV and mRNA production, providing 2-8x higher yields through proprietary backbone design, high-fidelity E. coli strain, and optimized purification and linearization processes.
- π-Icosa™ AAV Serotype Screening Platform AAV capsid engineering platform providing clients with novel capsid variants, including the AAV.eM muscle-specific capsid, via AI-assisted prediction of manufacturability combined with in vivo screening and validation, enabling tissue-targeted gene therapy applications across muscle, eye, brain, liver, and T cells.
- AAV Virus Packaging Service CRO service packaging recombinant AAV vectors at research-grade (5E11GC scale and above), HT-grade, and NHP-grade with titer detection and quality control for academic researchers and biotech clients across gene therapy, neuroscience, ophthalmology, and rare disease programs.
- Lentivirus Packaging Service CRO service packaging lentiviral vectors for cell-level and animal-level applications with rapid 10-12 working day delivery, qPCR titer quantification, safety and shipping support for gene therapy, cell therapy, and CAR-T developers as well as academic researchers.
- mRNA and mRNA-LNP Custom Service Custom mRNA synthesis and mRNA-LNP formulation service from research-grade through GMP-grade production for vaccine and therapeutic developers, including off-the-shelf mRNA products, with optimized LNP formulations for cellular uptake and reduced immunogenicity.
- piVector Online Vector Design Platform Self-serve online platform enabling customers to design and order custom AAV and lentiviral plasmids via drag-and-drop assembly with integrated ordering and after-sales support, reducing vector engineering time for research customers.
- AAV Off-the-Shelf Products Catalog of ready-to-use AAV products covering fluorescent proteins, optogenetics, chemogenetics, calcium indicators, recombinases, and gene editing tools in over 100 variants, sold directly via the order.packgene.com platform for neuroscience, ophthalmology, and gene editing research customers.
- Gene-to-AAV One-Stop Service Integrated CRO package delivering AAV-ready material in approximately 4 weeks by bundling gene synthesis, vector construction, plasmid preparation, virus packaging, and titer detection for researchers seeking accelerated turnaround from gene-of-interest to packaged AAV.
- AAV Serum Type Screening Service Service providing novel capsid screening and validation against muscle, eye, brain, liver, and T-cell targets to gene therapy developers seeking tissue-specific AAV tropism and detargeted liver expression for safer and more effective gene therapy candidates.
- AAV Library Service Custom AAV library construction and screening service for gene therapy researchers requiring diverse capsid pools to identify variants with improved precision, reduced off-target effects, and improved efficacy.
- AAV Analysis and Testing Services Analytical testing service offering titer, purity, and safety assays for AAV vectors using 60+ quality control tests and 110+ analytical methods, supporting release testing and characterization for both research and GMP-stage gene therapy programs.
- Plasmid Preparation Service Plasmid DNA production service delivering research-grade and preclinical-grade high-purity plasmids for AAV production and other gene therapy applications.
- GMP AAV Production GMP-grade AAV CDMO service spanning cell banking, process development, upstream and downstream optimization, fill-finish, and quality release testing across the 10L to 2000L scale using 6 cGMP production lines, supporting IIT, IND, and commercial BLA submissions under ISO9001 quality systems at the Guangzhou and Houston cGMP bases.
- GMP Plasmid Production GMP-grade plasmid DNA CDMO service supporting AAV and mRNA production at 5L to 200L scale across 2 cGMP plasmid lines as a starting material for gene therapy manufacturing programs.
- GMP mRNA and LNP GMP-grade mRNA and LNP CDMO service providing clinical and commercial supply of mRNA drug substances and lipid nanoparticle formulations for vaccine and therapeutic developers.
- ACCUBOX Mycoplasma Detection Kit Standalone mycoplasma detection kit sold as a product for quality control testing in AAV and cell therapy manufacturing workflows.
- Host Cell DNA Residual Detection Kits Line of residual host cell DNA detection kits covering E. coli, HEK293, and HEK293 DNA fragment analysis sold as standalone reagent products for quality control in AAV and cell therapy manufacturing.
Quantifiable outcome
- AAV yield increase of 5-20x through π-Alpha™ platform; downstream recovery rate >40%; per-batch yield up to 1×10¹⁷ vg
- +4 more outcomes
Companies that use PackGene Biotech, APAC
Customer profileNamed customers16 records
Segments3 records
Ideal customer profiles3 records
PackGene Biotech, APAC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
PackGene Biotech, APAC partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- 玛希隆大学 (Mahidol University) + Ramathibodi Hospital + Siriraj HospitalminorThai delegation from Mahidol University and two major hospitals visited PackGene. Thai partners plan to use PackGene's lentivirus and AAV vectors for thalassemia gene therapy R&D and clinical applications. Mahidol University and affiliated hospitals also willing to assist PackGene's global clients conducting clinical trials in Southeast Asia.
- Atlantis BioscienceminorJoint international webinar on AAV delivery and targeting strategies, hosted by PackGene and Atlantis Bioscience. Focused on overcoming AAV targeting challenges, immunogenicity, and efficacy through serotype development, gene sequence optimization, and production process optimization.
- 瑞风生物 (Ruifeng Bio)coreStrategic partnership for RM-101 (Usher syndrome) gene therapy. Supported FDA IND approval and NMPA IND approval in October 2024.
- 凌意生物 (Lingyi Bio)corePackGene provided high-quality CMC services for LY-M001 injection, China's first domestically developed gene therapy for Gaucher disease Type I. LY-M001 received NMPA IND clearance in January 2024 and FDA IND in January 2024. IIT study at Zhejiang University First Affiliated Hospital showed good safety and efficacy.
- 星眸生物 (Xingmou Bio)corePackGene provided full CMC services for XMVA09 (wet AMD) gene therapy, including plasmid and AAV process development, GMP production, analytical method development, quality research, release testing, stability studies, and complete CMC documentation. XMVA09 received NMPA CDE approval in March 2024.
- 神济昌华 (SineuGene Therapeutics)corePackGene provided AAV CDMO services including process development, GMP production, and quality research for SNUG01, the global first AAV gene therapy targeting TRIM72 for ALS. SNUG01 received FDA IND in March 2025 and NMPA IND in August 2025, supporting international multi-center clinical trials.
- 辉大基因 (HuiDa Gene)corePartner for HG004 for RPE65 mutation-related retinal disease. PackGene supported NMPA IND approval and international multi-region clinical trials.
- 金唯科生物 (Genevector/Jinweike)corePackGene provided one-stop analytical testing services for JWK001 (nAMD) and JWK002 (X-linked retinoschisis) AAV gene therapies. Supported method development, validation, release testing, stability studies, and characterization. JWK001 IND approved by NMPA in February 2024; JWK002 received FDA ODD, RPDD, and NMPA IND approval in 2025.
- 鼎新基因 (Dingxin Gene)corePackGene provided CDMO services for RRG001 (nAMD) gene therapy. RRG001 received IND approval and IIT was completed with positive outcomes.
- 暨南大学 (Jinan University)minorUniversity-enterprise cooperation: '大学生社会实践教学基地' officially established at PackGene. Students from Jinan University School of Pharmacy visit PackGene for industrial training. Seven consecutive years of collaboration.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
PackGene Biotech, APAC competitors and assessment
Company assessmentDirect peers
- Yposkesi: European AAV and lentiviral vector CDMO serving gene therapy developers. Comparable viral vector focus, GMP capabilities, and sponsor base.
- GenScript ProBio: China-headquartered CDMO with AAV, lentivirus, and plasmid manufacturing services. Comparable geographic footprint and CRO+CDMO one-stop model to PackGene.
- Forge Biologics: US-based AAV and gene therapy CDMO with integrated development, manufacturing, and analytical services. Closely comparable to PackGene as a pure-play viral vector CDMO targeting AAV gene therapy sponsors.
- Cobra Biologics (Charles River Laboratories): Gene therapy and viral vector CDMO within Charles River, offering AAV and lentivirus GMP manufacturing. Comparable services across research, clinical, and commercial stages.
- Andelyn Biosciences: AAV and lentivirus CDMO spun out of Nationwide Children's Hospital with GMP capacity. Directly comparable as a gene therapy-focused CDMO offering research-through-commercial AAV services.
Broad incumbents
- Catalent (Novo Holdings): Global CDMO with significant AAV and cell/gene therapy manufacturing capacity. Comparable GMP scale and customer base, but operating as a broader pharma services incumbent.
- Lonza: Global CDMO with established AAV and viral vector manufacturing services. Comparable GMP offering but operates as a broad incumbent across multiple modalities rather than AAV-pure-play.
- WuXi Biologics / WuXi Advanced Therapies: China-headquartered global biologics CDMO with growing AAV and cell/gene therapy capabilities. Comparable China footprint and CDMO scale, but broader biologics portfolio rather than AAV-specialized.
Regional players
- Porton Advanced: China-based CDMO focused on cell, gene, and nucleic acid therapies including AAV and plasmid manufacturing. Comparable domestic Chinese CDMO serving similar gene therapy entrepreneurs.
Emerging players
- ViroCell Biologics: UK-based AAV and lentiviral vector CDMO focused on clinical and commercial gene therapy supply. Comparable emerging AAV-specialized CDMO with similar sponsor base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
PackGene Biotech, APAC social profiles
Digital presencePackGene Biotech, APAC compliance and trust
Trust signalCompliance4 records
PackGene Biotech, APAC financial estimates
Financial estimateRevenue estimate
Valuation estimate
PackGene Biotech, APAC leadership team
Management profileNumber of profiles
Profiles5 records
PackGene Biotech, APAC subsidiaries and ownership
Company hierarchySubsidiaries1 record
PackGene Biotech, APAC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PackGene Biotech, APAC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PackGene Biotech, APAC
What does PackGene Biotech, APAC do?
PackGene Biotech is a one-stop CRO and CDMO platform for gene therapy vectors, providing recombinant AAV, lentivirus, mRNA/LNP, and plasmid DNA services from research-grade through GMP-grade production. Its offering spans vector design, process development, GMP manufacturing (10L-2000L scale), analytical testing (110+ methods), and regulatory CMC support covering IIT, IND, and BLA stages for global gene therapy developers and academic researchers.
Is PackGene Biotech, APAC a public or private company?
PackGene Biotech, APAC is a private company. It is classified as venture growth investor backed and is currently operating.
When was PackGene Biotech, APAC founded?
PackGene Biotech, APAC was founded in 2014. It employs 11 to 50 people.
Where is PackGene Biotech, APAC based?
PackGene Biotech, APAC is headquartered in Guangzhou (广州), China, in the Asia region.
How does PackGene Biotech, APAC make money?
Six revenue lines are on record. AAV Viral Vector CRO Services are the primary driver. The others are AAV GMP/CDMO Manufacturing Services, mRNA and LNP Services, lentivirus Packaging Services, plasmid DNA Production and detection Kits and Reagent Products.
Who are PackGene Biotech, APAC's main competitors?
Direct peers on record are Yposkesi, GenScript ProBio, Forge Biologics, Cobra Biologics (Charles River Laboratories) and Andelyn Biosciences. Broad incumbents are Catalent (Novo Holdings), Lonza and WuXi Biologics / WuXi Advanced Therapies. Porton Advanced is listed as a regional player. ViroCell Biologics is listed as an emerging player.
Does PackGene Biotech, APAC have an API?
No public API is recorded for PackGene Biotech, APAC.
What industry is PackGene Biotech, APAC in?
PackGene Biotech, APAC's product category is Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.